1. A method for generating a control voltage for a position actuator of a disk drive system for displacing a lens of a pick-up unit to a given position, wherein the actuator is operated by an open loop control system, said method comprising:
calibration of the control system for producing only a single control voltage (Va) from an input position signal (Xact_setp) to the control system;
processing only said single control voltage (Va) in a feed forward system for generating only a single processed control signal (Va_p), wherein said processing of only said single control voltage (Va) is performed as a function of the present axial (Z) position of the actuator, the present temperature, the (Z) position of the actuator during calibration, and the temperature during calibration,
feeding only said single processed control signal to said position actuator for displacing said lens to said given position
wherein said calibration step calibrates at least one of parameters K, R and C,
where K=property of \u2018actuator\u2019: NewtonAmpere
R=resistance of \u2018actuator\u2019 coil
C=Spring constant in Newtonmeter.
2. The method as claimed in claim 1, further comprising measuring a property dependent on an axial distance of the lens of the pick-up unit from a calibrated axial position, a Z-value, for use by said feed forward system and a temperature of the pick-up unit are measured.
3. The method as claimed in claim 1, further comprising measuring a property dependent on a temperature of the pick-up unit for use by said feed forward system.
4. The method as claimed in claim 1, in which said processed control signal is processed in dependence of an estimated distance of the lens from a calibrated axial position andor an estimated temperature of the pick-up unit.
5. The method as claimed in claim 1, in which said position actuator operates according to the formula:
Xdc=Va\u2014p*K(Temp,Z)(R(Temp)*C(Temp,Z))
in which
Xdc=position signal for said given position
Va_p=a processed control voltage
K=property of \u2018actuator\u2019 21: NewtonAmpere
R=resistance of \u2018actuator\u2019 coil
C=Spring constant in Newtonmeter.
6. The method as claimed in claim 5, in which the dependencies of temperature and Z-value of said parameters are estimated, and said processing step involves compensation of the dependency of said parameters by adjusting said control voltage to said processed control voltage.
7. The method as claimed in claim 1, wherein said processed voltage is calculated according to the formula:
Va\u2014p=Xact\u2014setp*Cal*S(Temp_cal,Z_cal)S(Temp_write,Z_write)
in which
Cal is the result of the calibration
S(Temp,Z)=(A\u2014T+B\u2014T*Temp+C\u2014T*Temp^2)*(A\u2014Z+B\u2014Z*Vz+C\u2014Z*Vz^2)
wherein
A_T, B_T, C_T, A_Z, B_Z, C_Z are constants;
Vz is the voltage across the Z actuator,
Temp_cal and Vz_cal are the temperature and Vz, respectively, during calibration,
Temp_write and Vz_write are the temperature and Vz, respectively, during writing.
8. A device for carrying out the method as claimed in claim 1, for generating a control voltage for a position actuator of a disk drive system for displacing a lens of a pick-up unit to a given position, wherein the actuator is operated by an open loop control system, said device comprising:
a calibration means for calibration of the control system for producing only a single control voltage (Va) from an input position signal (Xact_setp) to the control system;
a processing means for processing said only single control voltage in a feed forward system for generating only a single processed control signal (Va_p);
a position actuator for receiving said processed only single control signal and for displacing said lens to said given position
wherein said calibration means calibrates at least one of parameters K, R and C,
where K=property of \u2018actuator\u2019: NewtonAmpere
R=resistance of \u2018actuator\u2019 coil
C=Spring constant in Newtonmeter.
9. The device as claimed in claim 8, further comprising a temperature sensor.
10. The device as claimed in claim 8, further comprising a means for estimating the axial distance of the pick-up unit from a calibrated axial position, a Z-value, for example by means of an input of the actual actuator driver or by means of its output.
11. A method for generating a control voltage for a position actuator of a disk drive system for displacing a lens of a pick-up unit to a given position, wherein the actuator is operated by an open loop control system, said method comprising:
calibration of the control system for producing a control voltage (Va) from an input position signal (Xact_setp) to the control system;
processing said control voltage in a feed forward system for generating a processed control signal (Va_p);
feeding said processed control signal to said position actuator for displacing said lens to said given position
wherein said position actuator operates according to the formula:
Xdc=Va\u2014p*K(Temp,Z)(R(Temp)*C(Temp,Z))
in which
Xdc=position signal for said given position
Va_p=Va processed
K=property of \u2018actuator\u2019 21: NewtonAmpere
R=resistance of \u2018actuator\u2019 coil
C=Spring constant in Newtonmeter.
12. The method as claimed in claim 11, in which said calibration step calibrates at least one of said parameters K, R, C.
13. The method as claimed in claim 11, in which the dependencies of temperature and Z-value of said parameters are estimated, and said processing step involves compensation of the dependency of said parameters by adjusting said control voltage to said processed control voltage.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A pharmaceutical composition comprising:
an indolocarbazole compound present in a solubilized concentration ranging from about 3% up to about 9% by weight of the total composition; a hydrophilic polymer component; and water; wherein said composition is a microemulsion.
2. The composition according to claim 1, wherein said indolocarbazole is lestaurtinib or 9S-(9\u03b1, 10\u03b2,12\u03b1)-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo1,2,3-fg:3\u2032,2\u2032,1\u2032-klpyrrolo3,4-i1,6benzodiazocin-1-one.
3. The composition according to claim 1, wherein said indolocarbazole compound is lestaurtinib and said lestaurtinib is present in a solubilized concentration of between about 3% and about 9% of the total composition weight of the microemulsion.
4. The composition according to claim 1, wherein said hydrophilic polymer component comprises polyethylene glycol.
5. The composition according to claim 1, wherein said composition further comprises a surfactant.
6. The composition according to claim 5, wherein said surfactant is selected from the group consisting of anionic surfactants, cationic surfactants, and nonionic surfactants, and combinations thereof.
7. The composition according to claim 6, wherein said surfactant is a polyoxyethyl stearate.
8. The composition according to claim 1, further comprising an antioxidant component selected from the group consisting of H-atom donor antioxidant, sacrificial antioxidants and oxygen scavenger antioxidants, and combinations thereof.
9. The composition according to claim 8, wherein said antioxidant is selected from the group consisting of vitamin E, ascorbic acid, KMBS (potassium metabisulfite salt), ascorbyl palmitate, sodium ascorbate, BHA (butylated hydroxyanisole), BHT (butlyated hydroxytoluene) and combinations thereof.
10. An oral capsular dosage form comprising a pharmaceutical fill composition encapsulated within a capsule material, said composition comprising:
a) indolocarbazole compound present in an amount ranging from about 3% to about 9% per total composition weight;
b) a hydrophilic polymer component present in an amount ranging from about 30% to about 95% per total composition weight; and
c) water present in an amount ranging from about 0.8% to about 50% by weight of total composition weight;
wherein said composition is a microemulsion formulated for encapsulation with a hard capsule material.
11. The dosage form according to claim 10, wherein said capsule material is a hard capsule material selected from the group consisting of gelatin and hydroxypropylmethylcellulose.
12. The dosage form according to claim 10, wherein said indolocarbazole compound is lestaurtinib.
13. The dosage form according to claim 12, wherein said composition comprises:
a) lestaurtinib present in an amount from about 3% to about 9% total composition weight;
b) hydrophilic polymer component comprising a polyethylene glycol present in an amount from about 30% to about 90% total composition weight;
c) a surfactant comprising a polyoxyl stearate and present in an amount from about 5% to about 45% total composition weight;
d) water present in an amount from about 0.8% to about 15% total composition weight; and
e) an antioxidant component comprising a mixture of antioxidants and present in an amount from about 0.1% to about 2% total composition weight;
wherein said composition is in the form of a microemulsion and encapsulated within a hard capsule.
14. The dosage form according to claim 13, where said composition comprises:
a) lestaurtinib present in an amount from about 5% to about 7% total composition weight;
b) PEG-1000 present in an amount from about 35% to about 45% total composition weight;
c) MYRJ\xae 52 present in an amount from about 35% to about 45% total composition weight;
d) water present in an amount from about 6% to about 8% total composition weight;
e) vitamin E present in an amount which is about 0.075% total composition weight;
f) ascorbyl palmitate present in an amount which is about 0.1% total composition weight;
g) ascorbic acid present in an amount which is about 0.1% total composition weight; and
h) KMBS present in an amount which is about 0.2% total composition weight;
wherein said composition is in the form of a microemulsion and encapsulated within a hard capsule.
15. The dosage form according to claim 13, where said composition comprises:
a) lestaurtinib present in an amount from about 5% to about 7% total composition weight;
b) PEG-1000 present in an amount from about 35% to about 45% total composition weight;
c) MYRJ\xae 52 present in an amount from about 35% to about 45% total composition weight;
d) water present in an amount from about 6% to about 8% total composition weight;
e) vitamin E present in an amount which is about 0.075% total composition weight;
f) ascorbyl palmitate present in an amount which is about 0.1% total composition weight;
g) sodium ascorbate present in an amount which is about 0.125% total composition weight; and
h) KMBS present in an amount which is about 0.2% total composition weight;
wherein said composition is in the form of a microemulsion and encapsulated within a hard capsule.
16. The dosage form according to claim 13, where said composition comprises:
a) lestaurtinib present in an amount from about 5% to about 7% total composition weight;
b) PEG-1000 present in an amount from about 35% to about 45% total composition weight;
c) MYRJ\xae 52 present in an amount from about 35% to about 45% total composition weight;
d) water present in an amount from about 6% to about 8% total composition weight;
e) vitamin E present in an amount which is about 0.15% total composition weight;
f) ascorbyl palmitate present in an amount which is about 0.2% total composition weight; and
g) ascorbic acid present in an amount which is about 0.05% total composition weight;
wherein said composition is in the form of a microemulsion and encapsulated within a hard capsule.
17. The dosage form according to claim 13, where said composition comprises:
a) lestaurtinib present in an amount from about 5% to about 7% total composition weight;
b) PEG-1000 present in an amount from about 35% to about 45% total composition weight;
c) MYRJ\xae 52 present in an amount from about 35% to about 45% total composition weight;
d) water present in an amount from about 6% to about 8% total composition weight;
e) vitamin E present in an amount which is about 0.15% total composition weight; and
f) ascorbyl palmitate present in an amount which is about 0.2% total composition weight;
wherein said composition is in the form of a microemulsion and encapsulated within a hard capsule.
18. A pharmaceutical composition comprising a microemulsion having an indolocarbazole compound as an active ingredient present in a solubilized concentration ranging from about 3% up to about 9% of the total composition weight, said composition being prepared by:
a) combining an indolocarbazole compound, hydrophilic polymer component, and surfactant;
b) adding water to the combined ingredients from step a) in an amount sufficient to increase the solubilized concentration of said indolocarbazole compound to the desired concentration amount;
wherein steps a) and b) are performed at a temperature sufficient to form a molten liquid of the combined ingredients, facilitate solubilization of said indolocarbazole compound and form a microemulsion.
19. A process for increasing the solubilized concentration of an indolocarbazole compound in a microemulsion for a given fill volume, said process comprising:
a) combining an indolocarbazole compound, hydrophilic polymer component, and surfactant;
b) adding water to the combined ingredients from step a) in an amount sufficient to increase the solubilized concentration of said indolocarbazole compound to the desired concentration amount;
wherein steps a) and b) are performed at a temperature sufficient to form a molten liquid of the combined ingredients, facilitate solubilization of said indolocarbazole compound and form a microemulsion;
wherein said indolocarbazole is present in an amount of up to about 9% total composition weight.
20. A method of inhibiting receptor-tyrosine kinase in a recipient comprising orally administering to a recipient in need of such treatment an oral dosage form having a pharmaceutical composition comprising:
a) lestaurtinib present in a solubilized concentration of from about 3% to about 9% by weight of the total composition;
b) a hydrophilic polymer component comprising polyethylene glycol;
c) a surfactant; and
d) water;
wherein said composition is a microemulsion.
21. An oral tablet dosage form comprising a pharmaceutical composition, said composition comprising:
a) indolocarbazole compound present in an amount ranging from about 3% to about 9% per total composition weight;
b) a hydrophilic polymer component;
c) water; and
d) additional pharmaceutically acceptable excipients;
wherein said composition is a microemulsion formulated for compression into a tablet dosage form.
22. The dosage form according to claim 21, wherein said composition comprises:
a) lestaurtinib present in an amount which is about 3% total composition weight;
b) PEG-1000 present in an amount which is about 17% total composition weight;
c) water present in an amount which is about 4% total composition weight; and
d) additional pharmaceutically acceptable excipients selected from the group consisting of magnesium aluminometasilicate, microcrystalline cellulose, lactose, sodium starch glycolate and magnesium stearate;
wherein said composition is a microemulsion formulated for compression into a tablet dosage form.